

RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050



RealRate

July 10, 2026


To the CEO
Aurinia Pharmaceuticals
Inc
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
USA

Aurinia Pharmaceuticals Inc TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Aurinia Pharmaceuticals Inc has been TOP Rated at rank 9 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at <https://www.realrate.ai/rankings>. Your individual rating report, showing your strengths compared to your competitors is attached.



AuriniaTM

RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just \$9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: <https://calendly.com/holger-bartel>


Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Aurinia Pharmaceuticals Inc. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.



RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Aurinia Pharmaceuticals Inc (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	2026 US Pharmaceutical RealRate rating seal for Aurinia Pharmaceuticals Inc
Amount	USD 9,900
Order no.	2026-0001600620

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address


Company name	Full name
Street address	Department
City	Phone number
State / province	Email address
ZIP code	
Country	

Shipping address

The electronic RealRate rating seal and the invoice will be sent to
Delivery email

Aurinia Pharmaceuticals Inc

Date, location, name



The relative strengths and weaknesses of Aurinia Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aurinia Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Aurinia Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 5.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 394%, being 165% points above the market average of 229%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	491,967	Assets	751,587
Cost of Goods Sold	32,665	Liabilities	170,256
Intangible Assets	3,761	Expenses	9,426
Liabilities, Current	93,724	Revenues	283,055
Liabilities, Non-Current	17,548	Stockholders Equity	581,331
Other Assets	253,748	Net Income	287,202
Other Compr. Net Income	48	Comprehensive Net Income	287,226
Other Expenses	-157,538	BaseVar	613,972
Other Liabilities	58,984	ECR before LimitedLiability	337%
Other Net Income	13,573	Economic Capital Ratio	394%
Other Revenues	283,055		
Property and Equipment	2,111		
Research and Development	32,505		
Selling, General and Administrative Expense	101,794		